Vitality Watch

⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.

Mentioned 1× · first seen 07-oct-2026 · last seen 07-oct-2026

Partial Epigenetic Reprogramming (Yamanaka Factor Therapy)

Current understanding

Partial epigenetic reprogramming — transient expression of Yamanaka factors (typically OSK) via AAV to roll back epigenetic age without dedifferentiating cells — remains a mechanism-plausible longevity hypothesis with animal-model support (animal-model) and no completed human outcome trials. Life Biosciences has a formal optic-neuropathy program in the clinic pipeline; separately, KHL Foundation reports longevity-community individuals received AAV reprogramming constructs through medical-tourism providers ahead of any sanctioned first-in-human readout (anecdotal-biohack). No peer-reviewed human safety or efficacy data exist as of this entry.

Evidence log

Open questions

Related

Contributing findings

rss news report
KHL Foundation Reports the Likely First Human Partial Epigenetic Reprogramming Treatments
07-oct-2026 novelty 4 per-area 4 introduces

build build 880 · 2bcef25 · 2026-11-18